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Acuteaorticdissection(AAD)isaseriousvasculardisease.Currentlythediagnosisreliesonclinicalandradiologicalmeanswhereas
serum biomarkers are lacking. The purpose of this study was to identify potential serum biomarkers for AAD using isobaric tags
for relative and absolute quantitation (iTRAQ) approach. A total of 120 serum samples were collected from three groups: AAD
patients (n = 60), patients with acute myocardial infarction (AMI, n = 30), and healthy volunteers (n = 30), whereas the ﬁrst
10 samples from each group were used for iTRAQ analysis. Using iTRAQ approach, a total of 174 proteins were identiﬁed as
signiﬁcantly diﬀerent between AAD patients and healthy subjects. Among them, forty-six proteins increased more than twofold,
full-scale analysis using serum sample for the entire 120 subjects demonstrated that Lumican level was signiﬁcantly increased
relative to control and AMI samples. Further, Lumican level correlated with time from onset to admission in AAD but not AMI
samples. Using iTRAQ approach, our study showed that Lumican may be a potential AAD-related serum marker that may assist
the diagnosis of AAD.
1.Introduction
Acute aortic dissection (AAD) has become a treatable disease
due to recent advances in new therapeutic approaches for
the management of heart and arterial diseases; however,
development of quick and economic diagnostic methods
remains a challenge. Variability in disease presentation often
obscures diagnoses, and imaging modalities such as com-
puted tomography (CT), magnetic resonance imaging
(MRI), and esophagus ultrasound remain prohibitive due to
cost and availability. Aortic dissection remains a frequent
target of medicolegal litigations with accusations of failure
to diagnose against treating physicians and hospitals [1].
Some progress in the biochemical diagnosis of AAD has been
made in the last decade [2, 3]; several acute phase proteins
and coagulation parameters were identiﬁed to increase in
AAD patients, but these are nonspeciﬁc biomarkers for AAD
as they may be also aberrantly expressed in other disease
conditions such as acute myocardial infarction (AMI).
Recently a quantitative proteomic assay, isobaric tags for
relative and absolute quantitation (iTRAQ), has been devel-
oped and utilized to identify biomarkers for various disease
conditions [4, 5]. This chemical labeling method involves
the stable incorporation of isotopes into an amine tagging
reagent, which can then be reliably detected by mass
spectrometry, thereby permitting comparative quantitation
of various proteins in a multiplex manner. It has been
suggested to be suitable for the discovery of biomarkers in
a wide range of body ﬂuids and tissues, including serum
and plasma [5, 6]. With this method, we expect to ﬁnd the
potential biomarkers which are released from the disruption
of the aortic media and can provide suﬃcient speciﬁcity and
longer time window for the diagnosis of AAD.2 Journal of Biomedicine and Biotechnology
2.MaterialsandMethods
2.1. Samples. The study included a total of 30 healthy indi-
viduals and 90 patients (60 AAD, 30 AMI). All the patients
were selected in a consecutive manner from the period of
July 2009 to November 2011 from Fudan University aﬃliated
Zhongshan Hospital (Shanghai, China). iTRAQ analysis was
performed for the ﬁrst twenty patients (10 AAD and 10
AMI) and ten healthy individuals. All patients presented
within 72 hours after an episode of chest and/or back pain
lasting 5 minutes or more. The diagnosis of AAD was
conﬁrmed by computed tomographic arteriography (CTA).
The AMI patient was conﬁrmed by electrocardiography
(ECG) and cardiac troponin T (cTNT) tests. All patients
gave their informed consent for the study. The protocol was
approved by the Ethics Committee of Zhongshan Hospital.
For each study subject, whole blood samples were
immediately collected in BD Vacutainer SST tubes (BD
Diagnostics, Plymouth, UK) after admission and centrifuged
at 4000rpm for 10min at room temperature. The serum was
frozen and stored in aliquots at −80◦C until analysis.
2.2. Serum C-Reactive Protein and Myoglobin Test. Vitros
5.1 FS automatic biochemistry analyzer (Johnson & John-
son; Calif, USA) was used for serum C-reactive protein
(CRP) test, and Cobas e411 immunoassay analyzer (Roche;
Mannheim, Germany) was used for the serum myoglobin
(Myo) test. The results were then interpreted in accordance
with that tested by the International Federation of Clinical
Chemistry (IFCC) recommended method. Analyses were
performed immediately after the centrifugation of whole
blood samples.
2.3. iTRAQ Sample Preparation: Strong Cation Exchange
(SCX) Chromatography. iTRAQ reagents were purchased
from Applied Biosystems (Foster City, USA). Fourteen inter-
fering highly abundant proteins from serum samples were
removed using Agilent multiple aﬃnity removal liquid chro-
matography (LC) column-Human 14 (MARS) (shimadzu,
Kyoto, Japan). One hundred micrograms of each extract
were precipitated using acetone at −20◦C and suspended
in 20μL of dissolution buﬀer (Applied Biosystems, Foster
City, USA). After reduction and alkylation, each sample
was digested with trypsin (w(trypsin):w(protein) = 1:20)
at 37◦C overnight. The tryptic peptides were labeled with
t h ei T R A Qr e a g e n t sa sf o l l o w s :n o r m a lc o n t r o l sg r o u pw a s
labeledwithiTRAQ113,AMIgroupwaslabeledwithiTRAQ
114, and AAD group was labeled with iTRAQ 115. The
peptides were pooled and desalted with Sep-Pak Vac C18
(Waters, Milford, USA). The peptide mixture was diluted
withbuﬀerAcontaining10mMKH2PO4 in25%acetonitrile
(ACN) at pH 2.6. The peptides were fractionated by 20AD
high-performance liquid chromatography (HPLC) system
(Shimadzu; Kyoto, Japan) equipped with a polysulfoethyl A
column (2.1mm × 100mm, 5u, 200 A; The Nest Group,
Southborough, Mass). The composition of buﬀer B was
350mMKCl, 10mM KH2PO4, and 25% ACN at pH 2.6.
Separation was performed using a linear binary gradient of
0–80% buﬀer B in buﬀe rAa taﬂ o wr a t eo f2 0 0μL/min for
60min. The fractions were combined into 20 groups.
2.4. LC-MS Analysis. Each SCX fraction was dried down by
the rotary vacuum concentrator, dissolved in buﬀer C (0.1%
formicacid,5%ACN,95%water),andanalyzedonQstarXL
(Applied Biosystems; Foster City, USA). The HPLC gradient
was 5–35% buﬀer D (95% ACN, 0.1% formic acid) in buﬀer
C at a ﬂow rate of 300nL/min for 70min. Analysis survey
scans were acquired MS from m/z 400–1800 with up to 4
precursors selected for MS/MS from m/z 100–2000.
2.5. The Conﬁrmative ELISA Analysis for Lumican. The
conﬁrmative ELISA analysis for Lumican was performed
using the kits from CUSABIO BIOTECH CO, following
manufacture’s recommendation (CUSABIO BIOTECH CO.,
LTD., Wuhan, China).
2.6. Data Analysis. All statistical analyses were performed
in SPSS 12.0 (SPSS Inc. Chicago, USA). Results were pre-
sented as Mean ± SD. A comparative analysis of multiple
groups was performed with a one-way-ANOVA or Mann-
Whitney/Kruskal-Wallis Test. Statistical signiﬁcance was
deﬁned as P<0.05. Peptide and protein identiﬁcation
was performed by searching the MS/MS spectra against
the SwissProt database using the local Protein Pilot 2.0.1
software. Only peptides identiﬁed with conﬁdence interval
values of no less than 95% (Unused ProtScore >1.3) were
used for protein identiﬁcation compilation and subsequent
quantitation calculation. Fold changes of >2o r<0.5 were set
ascut-oﬀvaluestodesignatesigniﬁcantdiﬀerencesinprotein
expression among the AAD group and the normal control
group.
2.7. PANTHER Analysis. The PANTHER database was used
to elucidate cellular components, biological processes, and
the molecular functions associated with each individual pro-
tein (http://www.pantherdb.org/).
3. Results
3.1. Clinical Features of Study Subjects. The clinical features
of the AAD patients, AMI patients, and normal controls are
summarized in Table 1. There were no diﬀerences in age
distribution and sex composition among the three groups
involved either for ELISA analysis (N = 120) (P = 0.351 and
0.378, resp.,) or iTRAQ analysis (P = 0.241 and 0.873, resp.).
There was no diﬀerences in the time from onset to admission
between AAD and AMI group either (P = 0.776).
3.2. Functional Classiﬁcation of Identiﬁed Proteins by iTRAQ.
A total of 174 proteins with conﬁdence interval values of
no less than 95% were identiﬁed (Unused ProtScore > 1.3).
However, after manually rechecking the MS/MS data thor-
oughly peak by peak, 155 proteins (89.08%) had a relative
quantitation of one or more peptides. Fifteen proteins had
no quantiﬁable peptides that could be ascertained, and fourJournal of Biomedicine and Biotechnology 3
Table 1: Clinical characteristics in three groups.
AAD AMI Normal
controls P value
n 60 30 30
ELISA test
(N = 120)
Age (Mean ± SD) 55.63 ±16.39 59.70 ±13.98 59.50 ±12.65 0.351a
Gender, n (%),
male 30 (50) 17 (56.67) 16 (53.33) 0.378b
Admission after
onset hours
(Mean ± SD)
20.19 ±18.09 19.33 ±15.31 / 0.776c
Type A n (%) 31 (51.67) / /
Type B n (%) 29 (48.33) / /
Marfan n (%) 7 (11.67) / /
n 10 10 10
iTRAQ test
(N = 30)
Age (Mean ± SD) 51.60 ±13.22 61.00 ±5.25 49.9 ±15.02 0.241a
Gender, n (%),
male 6 (60) 6 (60) 5 (50) 0.873b
Admission after
onset hours
(Mean ± SD)
27.20 ±24.56 18.40 ±23.12 / 0.363c
Type A n (%) 5 (50) / /
Type B n (%) 5 (50) / /
Marfan n (%) 2 (20) / /
aOne-way-ANOVA; bChi-square Test; cMann-Whitney Test.
proteins had peptides with conﬁdence interval values that
were less than 95%.
In total, 174 proteins were sorted using the PANTHER
classiﬁcation system, which sorts the proteins into respective
categories based on their molecular functions. The major
groups include: signaling molecules (13%), enzyme modu-
lators (12%), transfer/carrier proteins (11%), and proteases
(10%). Other groups include: structural proteins (1%),
cell adhesion molecules (1%), cytoskeletal proteins (3%),
extracellularmatrixproteins(2%),andcelljunctionproteins
(1%).
As a way to cross-check the reliability of quantitation of
iTRAQ reagent, serum CRP and Myo levels were assessed
using both conventional biochemical and immunoassay
tests and iTRAQ analysis on the same specimens. With
biochemical and immunoassay analysis, CRP was 41.31 ±
32.76mg/mL and Myo was 66.42 ± 81.23mg/mL in AAD
group, while in normal controls, the former was 5.88 ±
1.42 and the latter was 32.07 ± 14.14mg/mL. CRP and
Myo levels of AAD patients were 7.03-fold and 2.07-fold
higher, respectively, than normal controls. Using iTRAQ, the
AAD/normal controls ratios of CRP and Myo were similar at
9.12-fold(Table 2)and1.47-fold.TheratiosofCRPandMyo
amongthreegroupsweresimilarwitheitherbiochemicaland
immunoassay or iTRAQ analysis, conﬁrming the reliability
of iTRAQ analysis.
3.3. Proteins with Over Twofold Diﬀerential Expression. A
total of 155 proteins had a relative quantitation diﬀerence
for AAD patients compared with the normal control group
of which 46 proteins increased more than twofold (Table 2),
while 36 proteins decreased more than twofold among the
AAD patients (Table 3). Among the identiﬁed proteins with
increased levels in AAD, there were a number of acute phase
reactants (CRP, Beta-2-microglobulin, Complement factor
I), blood coagulation marker (Haptoglobin, Coagulation
factor V, Coagulation factor IX), and cellular components
(Lumican, Tubulin beta-3 chain, Fibronectin). However
whencomparedtoAMIpatients,14ofthe46proteinshowed
less than 2-fold increase, including complement component
9, complement factor1, Plasma protein C1 inhibitor, and Ig
Kappa chain C-region (Table 2). Interestingly, some acute
phase proteins such as CRP remains on the list as it showed
the diﬀerential expression between the two conditions.
Among proteins with decreased expression in AAD
patients compared with normal controls, there were a num-
ber of molecules involved in protein metabolism (Inter-
alpha-trypsin inhibitor heavy chain H2, Alpha-2-HS-
glycoprotein), lipid metabolic process (Apolipoprotein A-IV,
Apolipoprotein E, Apolipoprotein C-I), blood coagulation
marker (Fibrinogen alpha chain, Prothrombin), and cellular
components (Alpha-2-HS-glycoprotein, thrombospondin-1
(TSP-1)). When compared to AMI patients, 8 of 36 proteins
did not reach the 2-fold diﬀerential expression (Table 3).
3.4. The ELISA Analysis of Serum Concentrations of Lumican.
Based on the iTRAQ ﬁndings above we selected two targets,
Fibronectin and Lumican, the protein markers potentially
associated with vascular injury, for the validation using
ELISA method. At the initial analysis using 10AAD and
10 normal samples we found that statistical signiﬁcant
diﬀerence between AAD and normal individual was seen for4 Journal of Biomedicine and Biotechnology
Table 2: List of the increased (>2-fold) protein targets identiﬁed and their corresponding class, associated biological process, and cellular
component.
NU n u s e d a Peptidesb Accession # Name Biological
process
Cellular
component Protein class AAD/CON
ratio
AAD/AMI
ratio
1 2.7 1 Q13509 Tubulin beta-3
chain
Cellular
component
morphogenesis
Cytoskelelton Cytoskeletal
protein/tubulin 39.8406 0.0711
2 2 1 P01600 Ig kappa chain
V-I region Hau Unclassiﬁed 31.3480 3.0760
3 6.67 3 P02743 Serum amyloid
P-component
Response to
stress
Defense/immunity
pro-
tein/antibacterial
response
24.4499 9.1241
4 13.53 10 P05546 Heparin cofactor
2
Protein
metabolic
process
Enzyme modulator 19.7628 11.2740
5 17.67 9 P36955
Pigment
epithelium-
derived
factor
Protein
metabolic
process
Enzyme modulator 19.7628 9.8135
6 6.24 4 P05543
Thyroxine-
binding
globulin
Protein
metabolic
process
Enzyme modulator 12.7065 3.7665
7 12.63 18 P01834 Ig kappa chain C
region
Response to
stimulus
Immunoglobulin
complex
Defense/immunity
protein 11.6959 1.8031
8 55.14 43 P02751 Fibronectin Blood
coagulation
Extracellular
matrix
Transfer/carrier
protein 11.5875 3.7327
9 35.94 29 P01011 Alpha-1-
antichymotrypsin
Protein
metabolic
process
Enzyme modulator 10.5708 8.0906
10 2.22 1 P02741 C-reactive
protein
Response to
stress
Defense/immunity
protein 9.1241 5.9701
11 2 1 Q9UK55
Protein
Z-dependent
protease inhibitor
Protein
metabolic
process
Enzyme modulator 8.7873 2.4888
12 100.78 51 P04114 Apolipoprotein
B-100
Lipid
metabolic
process
Transfer/carrier
protein 8.6281 2.8050
13 9.19 4 P35858
Insulin-like
growth
factor-binding
protein complex
acid labile chain
Cell-cell
adhesion
Extracellular
matrix Receptor 8.4746 4.0177
14 47.88 42 P19827
Inter-alpha-
trypsin inhibitor
heavy chain H1
Protein
metabolic
process
Enzyme modulator 5.8072 5.6497
15 106.72 89 P00450 Ceruloplasmin Blood
coagulation
Extracellular
matrix Transporter 5.1046 9.6339
16 37.56 23 P04196 Histidine-rich
glycoprotein
Blood
coagulation Unclassiﬁed 4.6125 3.2206
17 4.15 2 P08571
Monocyte
diﬀerentiation
antigen CD14
Immune
system process Receptor 4.0933 2.4888
18 2.72 1 Q96KN2 Beta-Ala-His
dipeptidase
Protein
metabolic
process
Protease 4.0933 1.9231
19 31.66 20 P01871 Ig mu chain C
region
Response to
stimulus
Defense/immunity
protein 3.8023 2.3552Journal of Biomedicine and Biotechnology 5
Table 2: Continued.
NU n u s e d a Peptidesb Accession # Name Biological
process
Cellular
component Protein class AAD/CON
ratio
AAD/AMI
ratio
20 12.12 6 P51884 Lumican Cell-cell
adhesion
Extracellular
matrix Receptor 3.6311 1.2942
21 2.71 1 P00740 Coagulation
factor IX
Blood
coagulation Protease 3.4037 2.0137
22 6.27 3 P08185
Corticosteroid-
binding
globulin
Protein
metabolic
process
Enzyme modulator 3.2808 5.4945
23 2.58 21 P00739
Haptoglobin-
related
protein
Unclassiﬁed 3.2206 1.7538
24 4.98 4 P04003
C4b-binding
protein alpha
chain
Blood
coagulation
Transfer/carrier
protein 3.1626 5.0582
25 6.02 6 P02745
Complement C1q
subcomponent
subunit A
Response to
stimulus
Transfer/carrier
protein 3.1046 3.6982
26 5.83 3 P22792 Carboxypeptidase
N subunit 2 Cell adhesion Extracellular
matrix Receptor 3.0202 1.3805
27 15.99 11 P05155 Plasma protease
C1 inhibitor
Protein
metabolic
process
Enzyme modulator 2.9647 1.2824
28 2.02 2 P01742 Ig heavy chain V-I
region EU Unclassiﬁed 2.8580 1.1695
29 2 1 P09486 SPARC Cell-cell
signaling
Transfer/carrier
protein 2.7042 0.7312
30 18.06 9 P02760 Protein AMBP Blood
coagulation Enzyme modulator 2.6062 3.5651
31 8.99 5 P12259 Coagulation
factor V
Blood
coagulation
Extracellular
matrix Transporter 2.6062 3.2206
32 8.31 6 P27169
Serum paraox-
onase/arylesterase
1
Immune
system process Oxidoreductase 2.5349 5.6497
33 2.32 1 P19320
Vascular cell
adhesion protein
1
Cell-cell
adhesion
Defense/immunity
protein 2.3121 2.1478
34 2.01 1 O00187
Mannan-binding
lectin serine
protease 2
Response to
stimulus Protease 2.3121 1.5277
35 43.19 29 P02749
Beta-2-
glycoprotein
1
Blood
coagulation
Transfer/carrier
protein 2.2287 7.1124
36 3.52 2 P11226 Mannose-binding
protein C
Response to
stimulus
Defense/immunity
protein 2.2080 2.6062
37 87.93 67 P00738 Haptoglobin Blood
coagulation Protease 2.1678 3.5651
38 5.7 4 Q13790 Apolipoprotein F
Lipid
metabolic
process
Transporter 2.1478 3.9448
39 65.42 41 P02790 Hemopexin Vitamin
transport
Transfer/carrier
protein 2.1478 3.9078
40 2.96 1 P20851
C4b-binding
protein beta
chain
Blood
coagulation
Transfer/carrier
protein 2.1281 4.83096 Journal of Biomedicine and Biotechnology
Table 2: Continued.
NU n u s e d a Peptidesb Accession # Name Biological
process
Cellular
component Protein class AAD/CON
ratio
AAD/AMI
ratio
41 2 1 P61769 Beta-2-
microglobulin
Response to
stimulus
Defense/immunity
protein 2.1088 2.1281
42 20.86 10 P02748 Complement
component C9
Response to
stimulus Receptor 2.1088 0.6252
43 6.96 3 P07477 Trypsin-1
Protein
metabolic
process
Protease 2.1088 0.3436
44 13.64 7 P05156 Complement
factor I
Response to
stimulus Protease 2.0325 0.9120
45 15.17 10 P01842 Ig lambda chain
C regions
Response to
stimulus
Immunoglobulin
complex
Defense/immunity
protein 2.0137 2.1678
46 4.29 1 P35030 Trypsin-3
Protein
metabolic
process
Protease 2.0137 1.3931
aUnused > 1.3 means at least 95% conﬁdence; bnumber of peptides with 95% conﬁdence; AAD: acute aortic dissection; AMI: acute myocardial infarction;
CON: normal controls.
AAD AMI Normal controls
0
1
2
3
4
L
u
m
i
c
a
n
(
n
g
/
m
L
)
Figure 1: Lumican levels were signiﬁcant diﬀerence between AAD,
AMI, and normal individuals (Mean ± SEM; P = 0.003).
Lumican but not Fibronectin (data not shown). Therefore,
we carried a full validation study only for Lumican, using
the entire 120 samples collected (see Table 1). A statistical
signiﬁcant diﬀerence between AAD, AMI, and normal
individual was seen in serum concentrations of Lumican
(2.66 ± 4.58ng/mL in AAD group, 0.69 ± 0.34ng/mL in
AMI group, and 0.85 ± 0.53ng/mL in normal control,
P = 0.003). The diﬀerence for AAD and AMI also reached
statistical signiﬁcance (P<0.05) suggesting the speciﬁcity
of this marker for AAD (Figure 1). We further analyzed the
correlation between Lumican levels with time from onset of
symptoms to admission. As shown in Figure 2,ac o r r e l a t i o n
was seen in AAD group (r = 0.256, P = 0.048) but not in
AMI group (r = 0.077, P = 0.685), further conﬁrming the
speciﬁcity of Lumican as a marker for AAD.
4. Discussion
iTRAQ analysis is recently been used as a potentially
more eﬀective biomarker discovery method than traditional
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Figure 2: Lumican levels were correlation with time from onset to
admission in AAD group (r = 0.256, P = 0.048), but not in AMI
group (r = 0.077, P = 0.685).
proteomic methods. The high reproducibility optimizes this
technique for embarking on “ﬁshing-expeditions” as an
initial screening for potential useful biomarkers [6–8]. As a
means of internal validation, the iTRAQ method was com-
paredwithCRPbiochemicalassayandMyoimmunoassay.In
our study there were no signiﬁcant diﬀerences in the serum
levelsdetermined bythe diﬀerent methods. Thus, the iTRAQ
method we employed appears in this preliminary analysis to
be suitable for the detection of relevant proteins.
To identify diﬀerentially expressed proteins, in many
studies, the cut-oﬀ points were set at 20% to 50% average
variance [7, 9, 10]. However, such approaches may result
in ﬁnding markers with low speciﬁcity [2, 3]. We therefore
appropriated to increase the cut-oﬀ point at 100% varianceJournal of Biomedicine and Biotechnology 7
Table 3: List of the decreased (<0.5 folds) protein targets identiﬁed and their corresponding class, associated biological process, and cellular
component.
NU n u s e d a Peptidesb Accession # Name Biological
process
Cellular
component
Protein
classiﬁcation
AAD/CON
ratio
AAD/AMI
ratio
1 19.31 17 P02775 Platelet basic
protein
Blood
coagulation
Transfer/carrier
protein 0.0209 0.0398
2 44.6 31 P02671 Fibrinogen alpha
chain
Blood
coagulation
Extracellular
matrix
Transfer/carrier
protein 0.0370 0.0203
3 19.82 30 P02656 Apolipoprotein
C-III
Lipid
metabolic
process
Transporter 0.0570 0.0240
4 5.7 5 P01717 Ig lambda chain
V-IV region Hil Unclassiﬁed 0.0655 0.0679
5 8.45 4 P02768 Serum albumin Transport Transfer/carrier
protein 0.0724 0.8472
6 3.22 1 P04264 Keratin, type II
cytoskeletal 1
Cellular
component
morphogenesis
Cytoskelelton Structural protein 0.0780 0.9639
7 2.05 1 P04070
Vitamin
K-dependent
protein C
Blood
coagulation Protease 0.0794 0.0441
8 34.98 27 P02652 Apolipoprotein
A-II
Lipid
metabolic
process
Transporter 0.0991 0.1067
9 20.3 10 P02654 Apolipoprotein
C-I
Lipid
metabolic
process
Transporter 0.1159 0.0847
10 94.94 108 P02765 Alpha-2-HS-
glycoprotein
Protein
metabolic
process
Extracellular
matrix
Extracellular
matrix protein 0.1180 0.1472
11 39.07 25 P01008 Antithrombin-III
Protein
metabolic
process
Enzyme
modulator 0.1202 0.0973
12 72.69 57 P00734 Prothrombin Blood
coagulation
Enzyme
modulator 0.1225 0.2051
13 6.88 3 P27918 Properdin Response to
stimulus Unclassiﬁed 0.1419 0.1905
14 6.31 4 P69905 Hemoglobin
subunit alpha
Blood
circulation
Transfer/carrier
protein 0.1500 0.2312
15 8.97 15 Q03591
Complement
factor H-related
protein 1
Blood
coagulation
Transfer/carrier
protein 0.1706 0.0991
16 27.03 22 P10909 Clusterin Apoptosis Unclassiﬁed 0.1905 0.1076
17 2 1 Q15942 Zyxin
Cellular
component
morphogenesis
Enzyme
modulator 0.1923 0.2109
18 20.4 26 P01024 Complement C3
Protein
metabolic
process
Transfer/carrier
protein 0.2070 0.1406
19 7.43 3 P17936
Insulin-like
growth
factor-binding
protein 3
Cell-matrix
adhesion Unclassiﬁed 0.2089 0.3162
20 2.23 2 P55290 Cadherin-13 Cell-cell
adhesion Cell junction Receptor 0.2188 0.1660
21 1.41 1 P13598
Intercellular
adhesion molecule
2
Cell-cell
adhesion
Transfer/carrier
protein 0.2355 0.16008 Journal of Biomedicine and Biotechnology
Table 3: Continued.
NU n u s e d a Peptidesb Accession # Name Biological
process
Cellular
component
Protein
classiﬁcation
AAD/CON
ratio
AAD/AMI
ratio
22 96.24 64 P00751 Complement
factor B
Blood
coagulation
Transfer/carrier
protein 0.2466 0.2729
23 28.82 16 P09871 Complement C1s
subcomponent
Blood
coagulation Protease 0.2606 0.4169
24 13.74 9 P01019 Angiotensinogen
Protein
metabolic
process
Enzyme
modulator 0.2630 0.5058
25 95.34 74 P19823
Inter-alpha-
trypsin inhibitor
heavy chain H2
Protein
metabolic
process
Enzyme
modulator 0.2805 0.5649
26 5.15 2 P18065
Insulin-like
growth
factor-binding
protein 2
Cell-matrix
adhesion Unclassiﬁed 0.2884 0.3281
27 16.84 10 P07996 Thrombospondin-
1
Blood
coagulation
Extracellular
matrix
Transfer/carrier
protein 0.3404 0.8317
28 5.31 3 P26927
Hepatocyte
growth factor-like
protein
Blood
coagulation
Transfer/carrier
protein 0.3436 0.3436
29 7.85 4 O14791 Apolipoprotein L1
Lipid
metabolic
process
Transporter 0.3908 0.2831
30 94.76 57 P06727 Apolipoprotein
A-IV
Lipid
metabolic
process
Transporter 0.4018 0.1837
31 14.1 9 P35527 Keratin, type I
cytoskeletal 9
Cellular
component
morphogenesis
Structural protein 0.4055 0.7244
32 9.48 6 P00746 Complement
factor D
Blood
coagulation Protease 0.4571 0.6668
33 48.09 24 P02649 Apolipoprotein E
Lipid
metabolic
process
Transporter 0.4656 0.2051
34 38.8 32 P02735 Serum amyloid A
protein
Immune
system process Transporter 0.4742 0.0319
35 9.46 5 P10720 Platelet factor 4
variant
Blood
coagulation
Transfer/carrier
protein 0.4742 0.5105
36 53.31 29 P02774 Vitamin
D-binding protein Transport Transfer/carrier
protein 0.4831 2.2287
aUnused > 1.3 means at least 95% conﬁdence; bnumber of peptides with 95% conﬁdence; AAD: acute aortic dissection; AMI: acute myocardial infarction;
CON: normal control.
in serum levels of candidate proteins between AAD patients
and normal subjects. Thus, only twofold changes below or
above normal controls were considered signiﬁcant. In our
study, total of 155 proteins had a relative diﬀerence between
AAD patients and healthy volunteers. Therefore, with higher
speciﬁcity, these candidate proteins are more likely to be
potential biomarkers for AAD.
In the group of signiﬁcantly increased proteins, there
were numerous acute phase reactants, such as Beta-2-mi-
croglobulin (P61769), which could be indicative of an in-
creased inﬂammatory response among AAD patients. CRP
(P02741), a protein found to be elevated in patients who
presented with symptoms or rupture of AAD and abdominal
aortic aneurysm, was also identiﬁed using iTRAQ [11, 12].
CRP is a nonspeciﬁc biomarker associated with AAD and a
predictor for long-term adverse events [13], and it can be
used to monitor evolution of false lumen thrombosis [14].
Unfortunately, CRP is also produced in coronary plaques
[15], acute myocardial infarction [16], and so forth. The
elevations of these acute phase reactants represent a gen-
eralized reaction to vascular injury, and as such, they are
nonspeciﬁc biomarkers. In addition, many proteins identi-
ﬁed are associated with blood coagulation and ﬁbrinolytic
system. Among which, ten had increased serum levelsJournal of Biomedicine and Biotechnology 9
(e.g., P00450-Ceruloplasmin, P02751-Fibronectin, P00738-
Haptoglobin...), and twelve had decreased serum levels
(e.g., P02671-Fibrinogen alpha chain, P00751-Complement
factor B, P00734-Prothrombin...). The pathophysiological
mechanism for the appearance of these proteins may be
explained by the release of tissue factors from the dissected
aortic wall then the activation of the extrinsic coagulation
system [17–19]. In addition, platelets can be activated by
injuries to the vessel wall, activation of the coagulation
cascade, or by activating factors released from stimulated
endothelial cells and platelets (e.g., ADP, thromboxane, von
Willebrand Factor). It also has been found that platelet func-
tions were aﬀected secondary to acute massive consumption
coagulopathy in the false lumen in AAD patient [20, 21].
In the past few years, extracellular matrix (ECM) com-
ponents of vessel walls such as elastin have been shown to be
elevated in aortic dissections; however, such increases were
less than twofold [3] .O u rs t u d yf o u n d9e x t r a c e l l u l a rm a t r i x
component proteins with greater than twofold diﬀerences,
among these are Carboxypeptidase (P22792), Lumican
(P51884), Fibronectin (P02751), Ceruloplasmin (P00450),
and Thrombospondin-1 (TSP-1, P07996). Fibronectin is a
polymorphic and multifunctional glycoprotein that plays
wide-ranging roles in tissue injury [22–25]. TSP-1, which is
an extracellular protein that participates in cell-to-cell and
cell-to-matrix communication, can stimulate or inhibit the
migration of vascular smooth muscle cells or endothelial
cells. It has been known as a plasma marker of peripheral
arterial disease [26].
Lumican is distributed in interstitial collagenous matri-
ces throughout the body. In coronary arteries ischemic
lesion, it is overexpressed by vascular smooth muscle cells
(VSMCs) [27] and also synthesized in aortic smooth muscle
cells [28]. In iTRAQ analysis, serum Lumican levels in
patients with AAD were 1.29-fold and 3.63-fold higher than
in patients with AMI and normal controls, respectively. It
is interesting to note that with iTRAQ analysis, the level of
diﬀerence between AAD and AMI for Lumican is less than
that of Fibronectin (Table 2), yet the initial validation using
ELISA method showed that only Lumican was signiﬁcantly
increased in AAD and AMI samples. While there may be
variety reasons to explain the variations of the ﬁndings
between the two methods, it highlights the importance of
validation in biomarker studies. The ﬁnding that Lumican
expression correlated with the time from onset to admission
only in AAD but not in AMI sample further conﬁrmed the
speciﬁcity of this protein in association with AAD.
Proteomic approach provides an exciting platform to
identifyclinicallyusefulproteinbiomarkers.Asaninitialstep
our study identiﬁed potential candidate protein biomarkers
in the serum of AAD patients with the iTRAQ technique.
However, the ultimate development of biomarkers which
provide suﬃcient sensitivity or speciﬁcity for the diagnosis
of AAD will require multiple validations and clinical testing,
which may include nonprotein markers. Nevertheless our
ﬁndings provide preliminary list of candidate biomarkers
that should be further validated, either alone or in combi-
nation.
5. Conclusion
In this paper, we found that iTRAQ technique is a suitable
approach for the detection of the new potential protein
markers in the serum of AAD patients. Using iTRAQ ap-
proach, our study identiﬁed that Lumican may be a po-
tentially interesting new serum marker of AAD, and upon
further validation this marker may assist the clinical diagno-
sis of AAD.
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